Eating one or more portions of broccoli every week can reduce the risk of prostate cancer, and the risk of localised cancer becoming more aggressive.

A simple blood test screening for a panel of biomarkers can accurately predict whether a patient who has had prostate cancer surgery will have a recurrence or spread of the disease.

Scientists at Dana-Farber Cancer Institute report they have blocked the development of prostate tumors in cancer-prone mice by knocking out a molecular unit they describe as a "powerhouse" that drives runaway cell growth.

Researchers at the Institute for Ultrafast Spectroscopy and Lasers (IUSL) at The City College of New York (CCNY) have conducted time-resolved fluorescence measurement and optical imaging studies that demonstrate the efficacy of Cytate as a fluorescence marker to detect prostate cancer.

A simple blood test may help doctors better predict whether prostate cancer will recur or spread in patients who have undergone surgery for the disease, UT Southwestern Medical Center researchers have found.

A simple blood test may help doctors better predict whether prostate cancer will recur or spread in patients who have undergone surgery for the disease, UT Southwestern Medical Center researchers have found.

The Access Act is gaining support from both sides of the aisle in congress and the senate. Several members of the Congressional Black Caucus have just signed on. Please write your representatives and senators to request their support of the Access Act.

A petition has been created (link below) that will also be sent to The Hill.

Members and Friends of CareToLive took to the streets in 10 cities across America on May 30, 2008. Why? To continue to tell the story about how some folks at the FDA were busy serving themselves when they were supposed to be serving the people of this great nation. To continue to tell the story about how 30,000 men, today, are in desperate need of a treatment for their prostate cancer, and how the FDA wrongly denied them some help.

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it has initiated a Phase 1 clinical trial for its Trofex molecular imaging program for the detection and staging of metastatic prostate cancer.

For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone – the hormone that fuels prostate-cancer growth – via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs.

Men with a certain type of prostate cancer have been shown to respond to a new chemotherapy drug, Sagopilone, plus prednisone in an international trial led by Oregon Health & Science University Cancer Institute researchers.

New cancer research from the University of Missouri suggests that eating a certain form of tomato product could be the key to unlocking the prostate cancer-fighting potential of the tomato. The positive effect of tomato products has been suggested in many studies, but, until now, researchers did not know exactly what caused this effect.